The use of human AHF (fraction I-0) in haemophilia A

Falsification or paradigm shift? Toward a revision of the common sense of transfusion

“…The development of the refrigerated centrifuge in 1954 allowed the separation of plasma soon after collection, allowing the preservation of the labile coagulation factors, something that was not immediately appreciated or applied. Developments in the understanding of the labile nature of antihemophilic factor (FVIII) led to the use of fresh or freshly frozen plasma to treat hemophilia A and subsequently its use as a raw material for the manufacture of the first FVIII concentrate, a crude modification of Cohn Fraction I 26 . The real breakthrough in the treatment of hemophilia A came when Judith Pool published her findings on cryoprecipitate in Nature 27 and the New England Journal of Medicine.…”

“…Developments in the understanding of the labile nature of antihemophilic factor (FVIII) led to the use of fresh or freshly frozen plasma to treat hemophilia A and subsequently its use as a raw material for the manufacture of the first FVIII concentrate, a crude modification of Cohn Fraction I. 26 The real breakthrough in the treatment of hemophilia A came when Judith Pool published her findings on cryoprecipitate in Nature 27 and the New England Journal of Medicine. 28 Pool showed that this component could be manufactured in a closed two-bag system by any blood bank possessing basic separation and freezing facilities, allowing the RBCs to be reconstituted with the residual plasma, which could also be separately harvested into a third bag.…”

Intracranial Surgery in Hemophiliacs

“…When long-term use is required, it is possible to alternate hu¬ man, canine, porcine, and bovine concen¬ trates, thereby avoiding allergic reactions and gradual loss of effectiveness.51 Concentrated human factor VIII was first used successfully in 1962. 52 Since this and certain subsequent preparations also con¬ tain fibrinogen, their administration leads to elevated plasma fibrinogen levels in the recipient, producing mild hemolysis and difficulty in cross matching due to impaired clot retraction. There is also the risk of serum hepatitis.53 "55 In 1965, two specific high potency cryoand glycine-precipitated factor-VIII concen¬ trates made from human plasma were de¬ veloped and are now in widest use.…”

25 years of published and unpublished coagulation‐therapy data for Haemate®P*

“…From the mid 1950's to the mid 1960's, a number of coagulation factor proteins were discovered and described, and plasma fraction 1-0 as well as cryoprecipitates became widely used (2,3). Cryoprecipitates were known to be high in FVIII content, and were readily producible and storable in more practical volumes than blood transfusion products.…”